Study analysis · British journal of sports medicine · 2026
Walking 7,500–10,000 steps a day—and hitting about 100 steps/min for your best 30 minutes—was linked to the lowest death risk in a 64,743-person study.
In older adults, taking more steps and walking faster during your best 30 minutes was linked to lower risk of dying, but the study can't prove cause and effect.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at whether people who walk more or walk faster are less likely to die early. It can show a link between walking habits and death rates, but it cannot prove that walking faster or more directly causes people to live longer. Other things like overall health could explain the link.
What’s the bottom line?
In a large study of older adults, people who took more steps and walked faster during their best 30 minutes had a lower risk of dying from any cause or heart disease. The best combination was 7,500–10,000 steps per day with a peak pace around 100 steps per minute.
How strong is this study?
The study followed a very large group of people over time and used wrist devices to measure walking, which is better than just asking people. But people weren't randomly assigned to walking habits, so we can't be sure other factors aren't responsible. Also, we only read a short summary, not the full details.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
25 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=64743)+20/20
- Follow-upno follow-up reported
100 / 100
54 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Prospective cohort design is observational; there is no randomization or experimental manipulation. Confounding by socioeconomic, health, and lifestyle factors cannot be fully controlled. Abstract only, so methodology cannot be fully verified. Associations may be bidirectional (reverse causation), and the temporal relationship between stepping intensity and mortality is not fully established.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information is provided in the abstract; therefore, COI severity cannot be assessed.
The provided text is an abstract only; it lacks author lists, affiliations, COI declarations, and funding statements. UK Biobank studies are typically publicly funded, but this cannot be confirmed from the text.
Key takeaways
- 01
Compared with 2,000 steps/day, 7,000 steps/day was linked to a 47% lower relative risk of death (absolute risk reduction not reported).
- 02
In people taking fewer than 5,000 steps/day, a peak pace of 80 steps/min was linked to a 28% lower relative risk of death (HR 0.72; absolute risk reduction not reported).
- 03
The lowest risk was at 7,500–10,000 steps/day and about 100 steps/min, with a 43% lower relative risk (HR 0.57; absolute risk reduction not reported).
- 04
Overall, 1,697 deaths occurred among 64,743 people, about 2.6% over the study period (about 26 per 1,000), but group-specific absolute risks were not reported.
- 05
The study did not report absolute risk for each group, so we cannot say exactly how many deaths were prevented per 1,000 people.
- 06
Overall, about 26 out of 1,000 participants died during follow-up.
- 07
The relative risk reductions (28–47% lower) are meaningful, but without baseline group risks, the absolute benefit remains unclear.
Practical takeaways
Consider aiming for 7,500–10,000 steps/day and a brisk peak 30-minute pace around 100 steps/min if safe and appropriate for you.
This is an observational association from an abstract only; absolute risk reduction was not reported, full paper was not available, and causation cannot be established.
low confidenceIf increasing daily steps is difficult, try adding short brisk walking bouts—the study found higher peak 30-min cadence was linked to lower mortality risk even in lower step-count groups.
The abstract does not report group-specific absolute risks or follow-up duration, and the design cannot prove that changing pace reduces death risk.
low confidenceWhy this study matters
The 7,500–10,000 steps/day sweet spot
In 64,743 UK Biobank participants (mean age 61.5 years; 1,697 deaths), the 7,500–10,000 steps/day group had the lowest all-cause mortality risk. The pattern was U-shaped, with lowest risk at about 100 steps/min peak 30-min cadence (HR 0.57, 95% CI 0.47–0.69; 43% lower relative risk). Absolute risk reduction was not reported; overall baseline absolute risk was about 2.6% (26 per 1,000) over the study period, but group-specific absolute risks were not specified.
This challenges the idea that more steps are always better and gives a concrete target range people can aim for.
Pace matters even if you take few steps
Among people taking fewer than 5,000 steps/day, a peak 30-min cadence of 80 steps/min was associated with a 28% lower relative risk of all-cause mortality (HR 0.72, 95% CI 0.54–0.97). In the 5,000–7,500 steps/day group, 60 steps/min was associated with a 30% lower relative risk (HR 0.70, 95% CI 0.58–0.86). Absolute risk reductions were not reported.
If you struggle to add steps, simply walking faster during your best 30 minutes may still be linked to lower risk.
From 2,000 to 7,000 steps/day
Compared with 2,000 steps/day, taking 7,000 steps/day was associated with a 47% lower relative risk of all-cause mortality. This is a relative risk reduction; absolute risk reduction was not reported. Overall, about 2.6% of participants died during follow-up.
7,000 steps is a more attainable goal than 10,000 for many people, and it was linked to a large relative risk reduction.
Heart deaths showed similar patterns
The abstract states that cardiovascular disease mortality results demonstrated similar dose–response patterns to all-cause mortality across peak 30-min cadence and step-count categories. However, specific hazard ratios for CVD mortality were not reported in the abstract.
It suggests the link isn't just about all-cause death but may extend to heart and blood vessel deaths.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In a large study of older adults, people who took more steps and walked faster during their best 30 minutes had a lower risk of dying from any cause or heart disease. The best combination was 7,500–10,000 steps per day with a peak pace around 100 steps per minute.
Research results
Compared with 2,000 steps/day, 7,000 steps/day was linked to a 47% lower relative risk of death (absolute risk reduction not reported). In people taking fewer than 5,000 steps/day, a peak pace of 80 steps/min was linked to a 28% lower relative risk of death (HR 0.72; absolute risk reduction not reported). The lowest risk was at 7,500–10,000 steps/day and about 100 steps/min, with a 43% lower relative risk (HR 0.57; absolute risk reduction not reported). Overall, 1,697 deaths occurred among 64,743 people, about 2.6% over the study period (about 26 per 1,000), but group-specific absolute risks were not reported.
What this means - more context
The study did not report absolute risk for each group, so we cannot say exactly how many deaths were prevented per 1,000 people. Overall, about 26 out of 1,000 participants died during follow-up. The relative risk reductions (28–47% lower) are meaningful, but without baseline group risks, the absolute benefit remains unclear.
To examine the joint association of stepping intensity (peak 30-min cadence) and daily step counts with all-cause mortality (ACM) and cardiovascular disease (CVD) mortality in older adults.
Prospective cohort study of 64,743 UK Biobank participants (mean age 61.5 years; 1,697 ACM events). Higher peak 30-min cadence was associated with lower ACM within step-count groups. The lowest ACM risk was at 7,500–10,000 steps/day with a U-shaped pattern and lowest at ~100 steps/min (HR 0.57, 95% CI 0.47–0.69; 43% lower relative risk). CVD mortality showed similar patterns. Compared with 2,000 steps/day, 7,000 steps/day was associated with a 47% lower relative risk of ACM. Absolute risk reductions were not reported. Overall baseline absolute risk was about 2.6% (26 per 1,000) over the study period, but follow-up duration and group-specific absolute risks were not specified in the abstract.
Methods Used
Prospective cohort using the UK Biobank wrist-worn accelerometer subsample. Peak 30-min cadence (PK30) was used as a stepping intensity metric. Daily steps were categorized as <5,000, 5,000–7,500, 7,500–10,000, and >10,000 steps/day. Multivariable-adjusted dose–response associations with ACM/CVD mortality were examined using Cox proportional and Fine and Gray subdistribution hazard models. Follow-up duration not specified in abstract.
Main Finding
Higher PK30 was associated with lower ACM risk in the <5,000 steps/day group (e.g., 80 steps/min: HR 0.72, 95% CI 0.54–0.97; 28% lower relative risk) and in the 5,000–7,500 group (e.g., 60 steps/min: HR 0.70, 95% CI 0.58–0.86; 30% lower relative risk). The 7,500–10,000 steps/day group had the lowest ACM risk, with a U-shaped pattern and lowest risk at ~100 steps/min (HR 0.57, 95% CI 0.47–0.69; 43% lower relative risk). Higher PK30 at 90 steps/min was associated with lower ACM across all step groups (e.g., <5,000: HR 0.64, 95% CI 0.32–1.32; >10,000: HR 0.71, 95% CI 0.59–0.87). CVD mortality showed similar dose–response patterns. Compared with 2,000 steps/day, 7,000 steps/day was associated with a 47% lower relative risk of ACM. Absolute risk reductions were not reported; overall baseline absolute risk was about 2.6% (26 per 1,000) over the study period.
Confidence Level
Limited - based on abstract only, full methodology not available. Observational design cannot establish causation. Large sample and device-based measures are strengths, but absolute risk reductions and follow-up duration are not reported.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Observational design cannot establish causation
- •Absolute risk reductions not reported; only relative risks provided
- •Follow-up duration not specified in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
Consider aiming for 7,500–10,000 steps/day and a brisk peak 30-minute pace around 100 steps/min if safe and appropriate for you.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at whether people who walk more or walk faster are less likely to die early. It can show a link between walking habits and death rates, but it cannot prove that walking faster or more directly causes people to live longer. Other things like overall health could explain the link.
Strengths
- Large sample size (64,743 participants)
- Prospective cohort design with mortality follow-up
- Device-based objective measurement of stepping intensity and step counts
Weaknesses
- Observational design precludes causal inference
- Residual confounding likely
- Abstract only - full methodology not available
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
In a large study of older adults, people who took more steps and walked faster during their best 30 minutes had a lower risk of dying from any cause or heart disease. The best combination was 7,500–10,000 steps per day with a peak pace around 100 steps per minute.
Research results
Compared with 2,000 steps/day, 7,000 steps/day was linked to a 47% lower relative risk of death (absolute risk reduction not reported). In people taking fewer than 5,000 steps/day, a peak pace of 80 steps/min was linked to a 28% lower relative risk of death (HR 0.72; absolute risk reduction not reported). The lowest risk was at 7,500–10,000 steps/day and about 100 steps/min, with a 43% lower relative risk (HR 0.57; absolute risk reduction not reported). Overall, 1,697 deaths occurred among 64,743 people, about 2.6% over the study period (about 26 per 1,000), but group-specific absolute risks were not reported.
What this means - more context
The study did not report absolute risk for each group, so we cannot say exactly how many deaths were prevented per 1,000 people. Overall, about 26 out of 1,000 participants died during follow-up. The relative risk reductions (28–47% lower) are meaningful, but without baseline group risks, the absolute benefit remains unclear.
To examine the joint association of stepping intensity (peak 30-min cadence) and daily step counts with all-cause mortality (ACM) and cardiovascular disease (CVD) mortality in older adults.
Prospective cohort study of 64,743 UK Biobank participants (mean age 61.5 years; 1,697 ACM events). Higher peak 30-min cadence was associated with lower ACM within step-count groups. The lowest ACM risk was at 7,500–10,000 steps/day with a U-shaped pattern and lowest at ~100 steps/min (HR 0.57, 95% CI 0.47–0.69; 43% lower relative risk). CVD mortality showed similar patterns. Compared with 2,000 steps/day, 7,000 steps/day was associated with a 47% lower relative risk of ACM. Absolute risk reductions were not reported. Overall baseline absolute risk was about 2.6% (26 per 1,000) over the study period, but follow-up duration and group-specific absolute risks were not specified in the abstract.
Methods Used
Prospective cohort using the UK Biobank wrist-worn accelerometer subsample. Peak 30-min cadence (PK30) was used as a stepping intensity metric. Daily steps were categorized as <5,000, 5,000–7,500, 7,500–10,000, and >10,000 steps/day. Multivariable-adjusted dose–response associations with ACM/CVD mortality were examined using Cox proportional and Fine and Gray subdistribution hazard models. Follow-up duration not specified in abstract.
Main Finding
Higher PK30 was associated with lower ACM risk in the <5,000 steps/day group (e.g., 80 steps/min: HR 0.72, 95% CI 0.54–0.97; 28% lower relative risk) and in the 5,000–7,500 group (e.g., 60 steps/min: HR 0.70, 95% CI 0.58–0.86; 30% lower relative risk). The 7,500–10,000 steps/day group had the lowest ACM risk, with a U-shaped pattern and lowest risk at ~100 steps/min (HR 0.57, 95% CI 0.47–0.69; 43% lower relative risk). Higher PK30 at 90 steps/min was associated with lower ACM across all step groups (e.g., <5,000: HR 0.64, 95% CI 0.32–1.32; >10,000: HR 0.71, 95% CI 0.59–0.87). CVD mortality showed similar dose–response patterns. Compared with 2,000 steps/day, 7,000 steps/day was associated with a 47% lower relative risk of ACM. Absolute risk reductions were not reported; overall baseline absolute risk was about 2.6% (26 per 1,000) over the study period.
Confidence Level
Limited - based on abstract only, full methodology not available. Observational design cannot establish causation. Large sample and device-based measures are strengths, but absolute risk reductions and follow-up duration are not reported.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •Observational design cannot establish causation
- •Absolute risk reductions not reported; only relative risks provided
- •Follow-up duration not specified in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
Consider aiming for 7,500–10,000 steps/day and a brisk peak 30-minute pace around 100 steps/min if safe and appropriate for you.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at whether people who walk more or walk faster are less likely to die early. It can show a link between walking habits and death rates, but it cannot prove that walking faster or more directly causes people to live longer. Other things like overall health could explain the link.
Strengths
- Large sample size (64,743 participants)
- Prospective cohort design with mortality follow-up
- Device-based objective measurement of stepping intensity and step counts
Weaknesses
- Observational design precludes causal inference
- Residual confounding likely
- Abstract only - full methodology not available
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study followed a very large group of people over time and used wrist devices to measure walking, which is better than just asking people. But people weren't randomly assigned to walking habits, so we can't be sure other factors aren't responsible. Also, we only read a short summary, not the full details.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
25 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=64743)+20/20
- Follow-upno follow-up reported
100 / 100
54 / 100
- P-valuesno p-values reported
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 542 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Prospective cohort design is observational; there is no randomization or experimental manipulation. Confounding by socioeconomic, health, and lifestyle factors cannot be fully controlled. Abstract only, so methodology cannot be fully verified. Associations may be bidirectional (reverse causation), and the temporal relationship between stepping intensity and mortality is not fully established.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information is provided in the abstract; therefore, COI severity cannot be assessed.
The provided text is an abstract only; it lacks author lists, affiliations, COI declarations, and funding statements. UK Biobank studies are typically publicly funded, but this cannot be confirmed from the text.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Menno Henselmans cite this study, drawing 2 claims from it.
Authored by
6 researchersIf this is your work, this is how we attribute it on Fit Body Science. Le Wei is listed as the lead author.